Develops miniature, removable drug implants designed to deliver long-acting medicines for chronic diseases in people and companion animals.
10-K for FY2025, filed Mar 26, 2026Vivani Medical, Inc. (“Vivani,” the “Company,” “we,” “us,” “our” or similar terms) is a clinical stage biopharmaceutical company which…View ↗
At Vivani, we are developing a portfolio of miniature, ultra long-acting subdermal drug implant candidates based on our NanoPortal…View ↗
Our emerging portfolio of miniature, ultra long-acting drug implant candidates have the potential to revolutionize the treatment of chronic…View ↗
Vivani develops implant candidates itself or with pharmaceutical partners. For commercialization, it plans to work with a large pharmaceutical company or use its own sales network, distributors or contract sales teams.
10-K for FY2025, filed Mar 26, 2026
10-Q for Q3 FY2026, filed Nov 12, 2026
−$7.3MView ↗
8-K, filed Nov 12, 2026
On October 30, 2026, the Company filed an current report on Form 8-K with the U.S. Securities and Exchange Commission to clarify that the…View ↗
Broader implant portfolio
The older report centered on an implant for type two diabetes; the latest describes implants for weight management, diabetes and companion animals, while prioritizing the obesity program.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026
Neurostimulation assets moved into Cortigent
The older report described neurostimulation as a division with strategic options under review; the latest says those assets were contributed to Cortigent and outlines potential routes to make it a separate company.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 26, 2026
Competes with Lilly, Novo Nordisk, AstraZeneca, Sanofi, Altimmune, Alveus, Amgen, Ascletis Pharma, Biomea, D&D Pharmatech, Fractyl Health, Gan & Lee, Innovent, Chugai, Mardigal, CSPC, Merck, Mindrank, OPKO Health, and Pfizer
10-K for FY2025, filed Mar 26, 2026The competition for Vivani will be dependent upon the individual product candidate in development. For Vivani’s lead programs, NPM-139…View ↗
Loading...